A review of robotic surgery in the management of recurrent ovarian carcinoma: indication and techniques

Background: Treatment of recurrent ovarian cancer may consist of salvage chemother-apy or secondary cytoreductive surgery. Retrospective studies suggest that radical secondary cytoreduction resulting in no macroscopic disease (R0) after completion of surgery benefits patients and prolongs survival. The role of robotic-assisted secondary cytoreductive surgery (RASCS) is in its infancy. The aim of this manuscript is to review the literature regarding the role, the indication, and the techniques of RASCS and to summarize the published perioperative, postoperative, and oncologic outcomes of RASCS. Methods: A comprehensive systemic review was conducted in the PubMed, MEDLINE, EMBASE, and Google Scholar databases from 1 January 1980 through 31 December 2021. Keywords searched were “ovarian cancer”, “recurrence”, “robotic-assisted secondary debulking/cytoreductive surgery”, “morbidity and mortality of secondary cytoreductive surgery”, “indications for secondary cytoreductive”, and combinations of these terms. Studies selected and analyzed included randomized controlled trials (RCTs) as well as prospective and retrospective anlayses and case series. RASCS procedures and techniques are described. Results: Several retrospectives, meta-analyses and prospective randomized trials suggest that optimal secondary cytoreductive surgery is associated with extended progression-free and overall survival. Preoperative selection criteria, such as Memorial Sloan Kettering (MSK) criteria and AGO (Arbeitsgemeinschaft Gynaekologische Onkologie) scores demonstrate that clinical-pathological factors can predict optimal secondary cytoreductive surgery and correlate with improved progression-free survival and overall survival. The surgical procedures that are required in secondary cytoreductive surgery can be complex. Limited retrospective studies have demonstrated that secondary cytoreductive surgery utilizing a robotic surgical platform can achieve the same rate of optimal cytoreductive surgery as open laparotomy with decreased morbidity. The effect of RASCS on progression-free and overall survival has not been established. Conclusions: Early literature reports indicate that RASCS, in selected patients, can be applied for surgical treatment of recurrent ovarian cancer without compromising morbidity; long-term studies are warranted to determine the effect on progression-free and overall survival.

Recurrent ovarian cancer; Secondary cytoreductive surgery; Robotic-assisted secondary cytoreductive surgery; RASCS

[1] Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. Journal of Clinical Oncology. 2002; 20: 1248–1259.

[2] Delgado G, Oram DH, Petrilli ES. Stage III epithelial ovarian cancer: the role of maximal surgical reduction. Gynecologic Oncology. 1984; 18: 293–298.

[3] Hacker NF, Berek JS, Lagasse LD, Nieberg RK, Elashoff RM. Primary cytoreductive surgery for epithelial ovarian cancer. Obstetrics and Gynecology. 1983; 61: 413–420.

[4] Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT, Berman M, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. American Journal of Obstetrics and Gynecology. 1994; 170: 974–979.

[5] Piver MS, Lele SB, Marchetti DL, Baker TR, Tsukada Y, Emrich LJ. The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma. Journal of Clinical Oncology. 1988; 6: 983–989.

[6] Burke TW, Morris M. Secondary cytoreductive surgery for ovarian cancer. Obstetrics and Gynecology Clinics of North America. 1994; 21: 167–178.

[7] Ushijima K. Treatment for recurrent ovarian cancer-at first relapse. Journal of Oncology. 2010; 2010: 497429.

[8] Colombo N, Sessa C, Bois AD, Ledermann J, McCluggage W, McNeish I, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. International Journal of Gynecologic Cancer. 2019; 30: 672–705.

[9] Lee CK, Lord S, Grunewald T, Gebski V, Hardy-Bessard A, Sehouli J, et al. Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial. Gynecologic Oncology. 2015; 136: 18–24.

[10] Fotopoulou C, Zang R, Gultekin M, Cibula D, Ayhan A, Liu D, et al. Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation. Annals of Surgical Oncology. 2013; 20: 1348–1354.

[11] Cianci S, Ronsini C, Vizzielli G, Tropea A, Biondi A, Scambia G, et al. Cytoreductive surgery followed by HIPEC repetition for secondary ovarian cancer recurrence. Updates in Surgery. 2019; 71: 389–394.

[12] Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. The Lancet. Oncology. 2017; 18: 779–791.

[13] Du Bois A, Sehouli J, Vergote I, Ferron G, Reuss A, Meier W, et al. Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: Final analysis of AGO DESKTOP III/ENGOT-ov20. Journal of Clinical Oncology. 2020; 38: 6000–6000.

[14] Bacalbasa N, Balescu I, Dimitriu M, Iliescu L, Diaconu C, Dima S, et al. The Influence of the Preoperative Status on the Risk of Postoperative Complications after Cytoreductive Surgery for Advanced-stage Ovarian Cancer. In Vivo. 2020; 34: 839–844.

[15] Magrina JF, Cetta RL, Chang Y, Guevara G, Magtibay PM. Analysis of secondary cytoreduction for recurrent ovarian cancer by robotics, laparoscopy and laparotomy. Gynecologic Oncology. 2013; 129: 336–340.

[16] Escobar PF, Levinson KL, Magrina J, Martino MA, Barakat RR, Fader AN, et al. Feasibility and perioperative outcomes of robotic-assisted surgery in the management of recurrent ovarian cancer: a multi-institutional study. Gynecologic Oncology. 2014; 134: 253–256.

[17] Berek JS, Hacker NF, Lagasse LD, Nieberg RK, Elashoff RM. Survival of patients following secondary cytoreductive surgery in ovarian cancer. Obstetrics and Gynecology. 1983; 61: 189–193.

[18] Oksefjell H, Sandstad B, Tropé C. The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer. Annals of Oncology. 2009; 20: 286–293.

[19] Scarabelli C, Gallo A, Carbone A. Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecologic Oncology. 2001; 83: 504–512.

[20] Tian W, Jiang R, Cheng X, Tang J, Xing Y, Zang R. Surgery in recurrent epithelial ovarian cancer: benefits on Survival for patients with residual disease of 0.1-1 cm after secondary cytoreduction. Journal of Surgical Oncology. 2010; 101: 244–250.

[21] Sehouli J, Richter R, Braicu EI, Bühling KJ, Bahra M, Neuhaus P, et al. Role of secondary cytoreductive surgery in ovarian cancer relapse: who will benefit? A systematic analysis of 240 consecutive patients. Journal of Surgical Oncology. 2010; 102: 656–662.

[22] Al Rawahi T, Lopes AD, Bristow RE, Bryant A, Elattar A, Chattopadhyay S, et al. Surgical cytoreduction for recurrent epithelial ovarian cancer. The Cochrane Database of Systematic Reviews. 2013; 2013: CD008765.

[23] Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecologic Oncology. 2009; 112: 265–274.

[24] Margul D, Coleman RL, Herzog TJ. The current status of secondary cytoreduction in ovarian cancer: a systematic review. Clinical Advances in Hematology & Oncology. 2020; 18: 332–343.

[25] Chi DS, McCaughty K, Diaz JP, Huh J, Schwabenbauer S, Hummer AJ, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer. 2006; 106: 1933–1939.

[26] Minaguchi T, Satoh T, Matsumoto K, Sakurai M, Ochi H, Onuki M, et al. Proposal for selection criteria of secondary cytoreductive surgery in recurrent epithelial ovarian, tubal, and peritoneal cancers. International Journal of Clinical Oncology. 2016; 21: 573–579.

[27] Angioli R, Capriglione S, Aloisi A, Ricciardi R, Scaletta G, Lopez S, et al. A Predictive Score for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer (SeC-Score): a Single-Centre, Controlled Study for Preoperative Patient Selection. Annals of Surgical Oncology. 2015; 22: 4217–4223.

[28] Tian W, Chi DS, Sehouli J, Tropé CG, Jiang R, Ayhan A, et al. A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection. Annals of Surgical Oncology. 2012; 19: 597–604.

[29] Harter P, du Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Annals of Surgical Oncology. 2006; 13: 1702–1710.

[30] Harter P, Sehouli J, Reuss A, Hasenburg A, Scambia G, Cibula D, et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. a project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. International Journal of Gynecological Cancer. 2011; 21: 289–295.

[31] Bogani G, Tagliabue E, Signorelli M, Ditto A, Martinelli F, Chiappa V, et al. A score system for complete cytoreduction in selected recurrent ovarian cancer patients undergoing secondary cytoreductive surgery: predictors- and nomogram-based analyses. Journal of Gynecologic Oncology. 2018; 29: e40.

[32] van de Laar R, Massuger LFAG, Van Gorp T, IntHout J, Zusterzeel PLM, Kruitwagen RFPM. External validation of two prediction models of complete secondary cytoreductive surgery in patients with recurrent epithelial ovarian cancer. Gynecologic Oncology. 2015; 137: 210–215.

[33] Shi T, Zhu J, Feng Y, Tu D, Zhang Y, Zhang P, et al. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology. 2021; 22: 439–449.

[34] Harter P, Sehouli J, Vergote I, Ferron G, Reuss A, Meier W, et al. Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer. New England Journal of Medicine. 2021; 385: 2123–2131.

[35] Eriksson AGZ, Graul A, Yu MC, Halko A, Chi DS, Zivanovic O, et al. Minimal access surgery compared to laparotomy for secondary surgical cytoreduction in patients with recurrent ovarian carcinoma: Perioperative and oncologic outcomes. Gynecologic Oncology 2017; 146: 263–267.

[36] Holloway RW, Brudie LA, Rakowski JA, Ahmad S. Robotic-assisted resection of liver and diaphragm recurrent ovarian carcinoma: description of technique. Gynecologic Oncology. 2011; 120: 419–422.

[37] Paterniti TA, Ahmad S, Holloway RW. Robotic-Assisted Laparoscopic Splenectomy for Recurrent Ovarian Cancer. International Journal of Gynecological Cancer 2020; 30: 1189–1194.

[38] Katebi Kashi P, Rojas C, Casablanca Y, Garg R. A seven-step surgical strategy for robotic splenectomy. International Journal of Gynecological Cancer. 2020; 30: 1079–1080.

[39] Tozzi R, Soleymani Majd H, Campanile RG, Ferrari F. Feasibility of laparoscopic diaphragmatic peritonectomy during Visceral-Peritoneal Debulking (VPD) in patients with stage IIIC-IV ovarian cancer. Journal of Gynecologic Oncology. 2020; 31: e71.

[40] Gkegkes ID, Karydis A, Tyritzis SI, Iavazzo C. Ocular complications in robotic surgery. The International Journal of Medical Robotics + Computer Assisted Surgery: MRCAS. 2015; 11: 269–274.

[41] Paek J, Kang E, Lim PC. Robotic lower pelvic port placement for optimal upper paraaortic lymph node dissection. Journal of Gynecologic Oncology. 2019; 29: e87.

[42] Lim PC, Kang EY. Feasibility and Survival Outcomes of Robotic Sec-ondary Debulking for Recurrent Ovarian Cancer. Journal of Minimally Invasive Gynecology. 2018; 25: S62–S63.